Outlook Therapeutics, Inc.
Panjang

$OTLK Outlook Therapeutics up 12% premarket, loads more to come.

618
This was a real winner yesterday and today is going to be the same, already up 12% pre market, we think there should be continuation in this name for days to come.
Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer

OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.